Tag Archives: Radiopharmaceutical Market

Radiopharmaceutical Market is expected to reach US$7.4 bn by the end of 2024

The global radiopharmaceutical market was valued at US$4.7 bn in 2015 and is estimated to reach US$7.4 bn by 2024, expanding at a CAGR of 5.3% from 2016 to 2024.

Nuclear Reactors Emerge as Key Source of Radiopharmaceuticals

By radioisotope, technetium-99 held the major share in the global radiopharmaceuticals market, accounting for 50.3% in 2016. The 18F segment, on the other hand, is projected to expand at a 5.5% CAGR from 2016 to 2024, higher than any other radioisotope.

View Report Overview: http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

Based on source, nuclear reactors lead the overall market in terms of revenue and the segment is also poised to eaxhibit a strong growth rate through 2024. Accounting for the dominant share in the radiopharmaceuticals market by end use, hospitals are likely to contribute significantly toward the growth of this market in the coming years. The others segment, which covers laboratories and universities, is anticipated to expand at the fastest pace despite being restricted to only the MEA and Asia Pacific regions.

Based on application, oncology took the lead owing to the growing use of various radioisotopes in the treatment of different cancers. On the basis of geography, North America is the clear leader and is slated to achieve a 60.3% share in the global radiopharmaceuticals market by 2024. Asia Pacific, on the other hand, will register a 6.3% CAGR from 2016 to 2024, emerging as the fastest expanding regional market in terms of revenue.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

Rising Incidence of Chronic Diseases Propelling Demand for Radiopharmaceuticals

The growing incidence of cancer and cardiovascular diseases – brought on by the rise in aging population, unhealthy food habits, prevalence of obesity – is one of the primary factors driving the radiopharmaceuticals market.

“The rising incidence of chronic diseases translates into the demand for diagnostic tests such as SPECT and PET, two of the latest systems used for the treatment of various cardiovascular and neurological diseases as well as cancer,” the TMR analyst states. According to the American Nuclear Society, 90% of the radioisotopes produced is used in gamma cameras or PET scan nuclear diagnostics. The remaining 10% is used in radioactive therapeutics drugs. This growing demand for diagnostic tests has a positive impact on the demand for radioisotopes and radiopharmaceuticals.

In addition to this, the rapid advancement in radiotracers and surging awareness regarding the effectiveness of radiopharmaceuticals will support the growth of the global market. On the other hand, stringent regulatory guidelines, a shortage in the supply of radioisotopes, and a shorter half-life of radiopharmaceuticals acts as impediments for the market.

Buy Radiopharmaceutical Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=213&ltype=S

The radiopharmaceutical market is highly consolidated, wherein the top two players – Siemens Healthineers and GE Healthcare – jointly accounted for over 70% of the global market in 2015. Transparency Market Research has observed that the degree of competition is rather high in the market owing to the presence of key players with the availability of advanced technologies and potential productive sources and a high product manufacturing capacity.

“Acquisitions play an important role among established organizations because they support sales, product development, and new methods of production,” the author of the report finds. An excellent example would be AAA. The company acquired GE Healthcare S.r.L’s FDG-PET business as well as the 100% shares of Imaging Equipment Ltd. (IEL) in 2014. These moves have enabled the company in strengthening its presence across Italy, the U.K., and Ireland.

 

Advertisements

Radiopharmaceutical Market value projected to expand by 2016 – 2024

The global radiopharmaceutical market was valued at US$4.7 bn in 2015 and is estimated to reach US$7.4 bn by 2024, expanding at a CAGR of 5.3% from 2016 to 2024.

Nuclear Reactors Emerge as Key Source of Radiopharmaceuticals

By radioisotope, technetium-99 held the major share in the global radiopharmaceuticals market, accounting for 50.3% in 2016. The 18F segment, on the other hand, is projected to expand at a 5.5% CAGR from 2016 to 2024, higher than any other radioisotope.

View Report Overview: http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

Based on source, nuclear reactors lead the overall market in terms of revenue and the segment is also poised to exhibit a strong growth rate through 2024. Accounting for the dominant share in the radiopharmaceuticals market by end use, hospitals are likely to contribute significantly toward the growth of this market in the coming years. The others segment, which covers laboratories and universities, is anticipated to expand at the fastest pace despite being restricted to only the MEA and Asia Pacific regions.

Based on application, oncology took the lead owing to the growing use of various radioisotopes in the treatment of different cancers. On the basis of geography, North America is the clear leader and is slated to achieve a 60.3% share in the global radiopharmaceuticals market by 2024. Asia Pacific, on the other hand, will register a 6.3% CAGR from 2016 to 2024, emerging as the fastest expanding regional market in terms of revenue.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

Rising Incidence of Chronic Diseases Propelling Demand for Radiopharmaceuticals

The growing incidence of cancer and cardiovascular diseases – brought on by the rise in aging population, unhealthy food habits, prevalence of obesity – is one of the primary factors driving the radiopharmaceuticals market.

“The rising incidence of chronic diseases translates into the demand for diagnostic tests such as SPECT and PET, two of the latest systems used for the treatment of various cardiovascular and neurological diseases as well as cancer,” the TMR analyst states. According to the American Nuclear Society, 90% of the radioisotopes produced is used in gamma cameras or PET scan nuclear diagnostics. The remaining 10% is used in radioactive therapeutics drugs. This growing demand for diagnostic tests has a positive impact on the demand for radioisotopes and radiopharmaceuticals.

In addition to this, the rapid advancement in radiotracers and surging awareness regarding the effectiveness of radiopharmaceuticals will support the growth of the global market. On the other hand, stringent regulatory guidelines, a shortage in the supply of radioisotopes, and a shorter half-life of radiopharmaceuticals acts as impediments for the market.

Buy Radiopharmaceutical Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=213&ltype=S

The radiopharmaceutical market is highly consolidated, wherein the top two players – Siemens Healthineers and GE Healthcare – jointly accounted for over 70% of the global market in 2015. Transparency Market Research has observed that the degree of competition is rather high in the market owing to the presence of key players with the availability of advanced technologies and potential productive sources and a high product manufacturing capacity.

“Acquisitions play an important role among established organizations because they support sales, product development, and new methods of production,” the author of the report finds. An excellent example would be AAA. The company acquired GE Healthcare S.r.L’s FDG-PET business as well as the 100% shares of Imaging Equipment Ltd. (IEL) in 2014. These moves have enabled the company in strengthening its presence across Italy, the U.K., and Ireland.

New Trends of Radiopharmaceutical Market with Worldwide Industry Analysis to 2024

A recent study by Transparency Market Research (TMR) has detected that the global radiopharmaceuticals market is consolidated in nature with two companies, GE Healthcare and Siemens Healthineers, holding 70% of the market in 2015. Radiopharmaceuticals make for an evolving market, which is attracting a number of other leading pharmaceutical players with technological capabilities and high production capacity. As a result, the competition is expected to get even stiffer in the near future.

The TMR report projects the global market for radiopharmaceuticals to increment demand at a CAGR of 5.3% during the forecast period of 2016 to 2024. According to the evaluations of the report, the global radiopharmaceuticals market was worth US$4.7 bn in 2015, and estimates it to reach a valuation of US$7.4 bn by the end of 2024.

Acquisition of niche players is the primary strategy adopted by these leading players to expand their geographical presence, while adopting new methods of production and robust sales support are other modes of maintain their stronghold over the market. For instance, AAA acquired GE Healthcare S.r.L’s FDG-PET business recently, after gaining full shares in Imaging Equipment Ltd. (IEL) in 2014. With these moves, the company has significantly strengthened their presence in the U.K., Italy, and Ireland.

This 246 page report gives readers a comprehensive overview of the radiopharmaceutical market. Browse through 36 data tables and 102 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

Technetium-99 Most Profitable Radioisotope Segment

On the basis of source, the report segments the global radiopharmaceutical market into nuclear reactors and cyclotrons, and rates the former as slightly more profitable market segment than the latter. End-users of radiopharmaceutical market analyzed under this report are hospitals, diagnostic centers, ambulatory surgical centers, and others. Hospitals continue to serve significantly more demand, although technological advancements is poised to increment ambulatory surgical centers segment quickly during the forecast period.

On the basis of radioisotope, the report categorizes the global radiopharmaceutical market into technetium-99, iodine-123, 18F, gallium-67, yttrium-90, rubidium-82, and lutetium-177. Among these, technetium-99 accounted for 50.3% of the demand in 2016, although the report projects 18F segment to exhibit the most prominent CAGR of 5.5% during the forecast period of 2016 to 2024. Application-wise, the report rates oncology as most profitable, while the segments of cardiology, immunology, and nephrology are also poised for healthy growth in the near future.

Currently, North America is the most lucrative region for the vendors operating in the global radiopharmaceutical market, which is a reflection of robust healthcare infrastructure in developed countries such as the U.S. and Canada. Owing to increasing number of cyclotron installations to produce radioisotopes for the treatment of cancer, Europe is also expected to serve significant demand in the global radiopharmaceutical market during the forecast period. However, Asia Pacific is also expected to turn into a profitable market for the early investors, as countries such as India and China are among the fastest growing economies and are actively improving their healthcare facilities. Commitment to technology for the development of new therapeutic isotopes, growing research and development interest in nuclear medicine, and rapid urbanization are some of the other factors favoring the Asia Pacific radiopharmaceutical market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving radiopharmaceutical market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

Prevalence of Cancer Driving Demand

Some of the key factors driving the global radiopharmaceutical market are: continued preference of radioisotopes for the diagnostic imaging, glaring benefits such as targeted therapeutic irradiation that have fewer side effects, easy detection of metastatic sites, positron emission tomography (PET), prevalence of cancer, and growing number of diagnostic, chemotherapy, and screen centers. On the other hand, strict regulations pertaining to the production and storage of radiopharmaceuticals is hindering the market for radiopharmaceutical from attaining its full potential.

The information presented in this review is based on a Transparency Market Research report, titled, “Radiopharmaceutical Market (Radioisotope – Technetium-99, Gallium-67, Iodine-123, 18F, Rubidium-82, Yttrium-90, and Lutetium-177; End User – Hospitals, Ambulatory Surgical Centers, and Diagnostic Centers; Source – Nuclear Reactor and Cyclotrons; Application – Cardiology, Gastroenterology, Oncology (Brachytherapy), Nephrology, Neurology, and Immunology) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024”

 

Radiopharmaceutical Market: Nuclear Reactors Emerge as Key Source of Radiopharmaceuticals

The radiopharmaceutical market is highly consolidated, wherein the top two players – Siemens Healthineers and GE Healthcare – jointly accounted for over 70% of the global market in 2015. Transparency Market Research has observed that the degree of competition is rather high in the market owing to the presence of key players with the availability of advanced technologies and potential productive sources and a high product manufacturing capacity.

“Acquisitions play an important role among established organizations because they support sales, product development, and new methods of production,” the author of the report finds. An excellent example would be AAA. The company acquired GE Healthcare S.r.L’s FDG-PET business as well as the 100% shares of Imaging Equipment Ltd. (IEL) in 2014. These moves have enabled the company in strengthening its presence across Italy, the U.K., and Ireland.

This 246 page report gives readers a comprehensive overview of the radiopharmaceutical market. Browse through 36 data tables and 102 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

The global radiopharmaceutical market was valued at US$4.7 bn in 2015 and is estimated to reach US$7.4 bn by 2024, expanding at a CAGR of 5.3% from 2016 to 2024.

Nuclear Reactors Emerge as Key Source of Radiopharmaceuticals

By radioisotope, technetium-99 held the major share in the global radiopharmaceuticals market, accounting for 50.3% in 2016. The 18F segment, on the other hand, is projected to expand at a 5.5% CAGR from 2016 to 2024, higher than any other radioisotope.

Based on source, nuclear reactors lead the overall market in terms of revenue and the segment is also poised to exhibit a strong growth rate through 2024. Accounting for the dominant share in the radiopharmaceuticals market by end use, hospitals are likely to contribute significantly toward the growth of this market in the coming years. The others segment, which covers laboratories and universities, is anticipated to expand at the fastest pace despite being restricted to only the MEA and Asia Pacific regions.

Based on application, oncology took the lead owing to the growing use of various radioisotopes in the treatment of different cancers. On the basis of geography, North America is the clear leader and is slated to achieve a 60.3% share in the global radiopharmaceuticals market by 2024. Asia Pacific, on the other hand, will register a 6.3% CAGR from 2016 to 2024, emerging as the fastest expanding regional market in terms of revenue.

Rising Incidence of Chronic Diseases Propelling Demand for Radiopharmaceuticals

The growing incidence of cancer and cardiovascular diseases – brought on by the rise in aging population, unhealthy food habits, prevalence of obesity – is one of the primary factors driving the radiopharmaceuticals market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving radiopharmaceutical market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

“The rising incidence of chronic diseases translates into the demand for diagnostic tests such as SPECT and PET, two of the latest systems used for the treatment of various cardiovascular and neurological diseases as well as cancer,” the TMR analyst states. According to the American Nuclear Society, 90% of the radioisotopes produced is used in gamma cameras or PET scan nuclear diagnostics. The remaining 10% is used in radioactive therapeutics drugs. This growing demand for diagnostic tests has a positive impact on the demand for radioisotopes and radiopharmaceuticals.

In addition to this, the rapid advancement in radiotracers and surging awareness regarding the effectiveness of radiopharmaceuticals will support the growth of the global market. On the other hand, stringent regulatory guidelines, a shortage in the supply of radioisotopes, and a shorter half-life of radiopharmaceuticals acts as impediments for the market.

This review is based on the findings of a TMR report titled “Radiopharmaceutical Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024.”

 

New Trends of Radiopharmaceutical Market with Worldwide Industry Analysis to 2024

The radiopharmaceutical market is highly consolidated, wherein the top two players – Siemens Healthineers and GE Healthcare – jointly accounted for over 70% of the global market in 2015. Transparency Market Research has observed that the degree of competition is rather high in the market owing to the presence of key players with the availability of advanced technologies and potential productive sources and a high product manufacturing capacity.

“Acquisitions play an important role among established organizations because they support sales, product development, and new methods of production,” the author of the report finds. An excellent example would be AAA. The company acquired GE Healthcare S.r.L’s FDG-PET business as well as the 100% shares of Imaging Equipment Ltd. (IEL) in 2014. These moves have enabled the company in strengthening its presence across Italy, the U.K., and Ireland.

This 246 page report gives readers a comprehensive overview of the radiopharmaceutical market. Browse through 36 data tables and 102 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

The global radiopharmaceutical market was valued at US$4.7 bn in 2015 and is estimated to reach US$7.4 bn by 2024, expanding at a CAGR of 5.3% from 2016 to 2024.

Nuclear Reactors Emerge as Key Source of Radiopharmaceuticals

By radioisotope, technetium-99 held the major share in the global radiopharmaceuticals market, accounting for 50.3% in 2016. The 18F segment, on the other hand, is projected to expand at a 5.5% CAGR from 2016 to 2024, higher than any other radioisotope.

Based on source, nuclear reactors lead the overall market in terms of revenue and the segment is also poised to exhibit a strong growth rate through 2024. Accounting for the dominant share in the radiopharmaceuticals market by end use, hospitals are likely to contribute significantly toward the growth of this market in the coming years. The others segment, which covers laboratories and universities, is anticipated to expand at the fastest pace despite being restricted to only the MEA and Asia Pacific regions.

Based on application, oncology took the lead owing to the growing use of various radioisotopes in the treatment of different cancers. On the basis of geography, North America is the clear leader and is slated to achieve a 60.3% share in the global radiopharmaceuticals market by 2024. Asia Pacific, on the other hand, will register a 6.3% CAGR from 2016 to 2024, emerging as the fastest expanding regional market in terms of revenue.

Rising Incidence of Chronic Diseases Propelling Demand for Radiopharmaceuticals

The growing incidence of cancer and cardiovascular diseases – brought on by the rise in aging population, unhealthy food habits, prevalence of obesity – is one of the primary factors driving the radiopharmaceuticals market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving radiopharmaceutical market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

“The rising incidence of chronic diseases translates into the demand for diagnostic tests such as SPECT and PET, two of the latest systems used for the treatment of various cardiovascular and neurological diseases as well as cancer,” the TMR analyst states. According to the American Nuclear Society, 90% of the radioisotopes produced is used in gamma cameras or PET scan nuclear diagnostics. The remaining 10% is used in radioactive therapeutics drugs. This growing demand for diagnostic tests has a positive impact on the demand for radioisotopes and radiopharmaceuticals.

In addition to this, the rapid advancement in radiotracers and surging awareness regarding the effectiveness of radiopharmaceuticals will support the growth of the global market. On the other hand, stringent regulatory guidelines, a shortage in the supply of radioisotopes, and a shorter half-life of radiopharmaceuticals acts as impediments for the market.

This review is based on the findings of a TMR report titled “Radiopharmaceutical Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024.”